Harborview Medical Center Study – AeroEclipse II® BAN – Reduction of 30 day re-admission rate and COPD LOS
Previous Post : AeroEclipse II<sup>®</sup> BAN Efficiency StudyNext Post : AEROECLIPSE<sup>®</sup> Breath Actuated Nebulizers (BAN)
JOIN US AT ATS 2026 INTERNATIONAL CONFERENCE: MAY 17-20, 2026 -- BOOTH 2201
